- TRADE NAMES: Avan; Catena (Santhera); Mnesis (Takeda)
- INDICATIONS: Alzheimer's dementia, cardiovascular disease, cerebrovascular disease, demyelination, depression, Friedreich's ataxia, improving memory, Leber's hereditary optic neuropathy
- CLASS: Coenzyme Q10 analog
- HALF-LIFE: N/A
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
